Page last updated: 2024-11-13
halocidin
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
halocidin: antimicrobial peptide from hemocytes of the solitary tunicate, Halocynthia [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 45272204 |
CHEMBL ID | 562966 |
MeSH ID | M0432832 |
Synonyms (2)
Synonym |
---|
CHEMBL562966 |
halocidin |
Research Excerpts
Overview
Halocidin is a heterodimeric antimicrobial peptide. It is isolated from hemocytes from the tunicate, Halocynthiaaurantium.
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Bioassays (8)
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID425046 | Antimicrobial activity against vancomycin-resistant Enterococcus faecium CCARM 5029 after 18 hrs by broth microdilution assay | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Antimicrobial effect of halocidin-derived peptide in a mouse model of Listeria infection. |
AID425043 | Antimicrobial activity against methicillin-resistant Staphylococcus aureus CCARM 3695 after 18 hrs by broth microdilution assay in presence of 150 mM NaCl | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Antimicrobial effect of halocidin-derived peptide in a mouse model of Listeria infection. |
AID425050 | Antimicrobial activity against methicillin-resistant Staphylococcus aureus CCARM 3695 treated with supernatant containing 2 mg drug incubated for 10 mins with PBS containing 50 % normal human serum centrifuged for 3 hrs by radial diffusion assay | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Antimicrobial effect of halocidin-derived peptide in a mouse model of Listeria infection. |
AID425044 | Antimicrobial activity against Listeria monocytogenes ATCC 19111 after 18 hrs by broth microdilution assay | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Antimicrobial effect of halocidin-derived peptide in a mouse model of Listeria infection. |
AID425051 | Antimicrobial activity against methicillin-resistant Staphylococcus aureus CCARM 3695 treated with supernatant containing 2 mg drug incubated for 10 mins with PBS centrifuged for 3 hrs by radial diffusion assay | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Antimicrobial effect of halocidin-derived peptide in a mouse model of Listeria infection. |
AID425045 | Antimicrobial activity against Listeria monocytogenes ATCC 19111 after 18 hrs by broth microdilution assay in presence of 150 mM NaCl | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Antimicrobial effect of halocidin-derived peptide in a mouse model of Listeria infection. |
AID425047 | Antimicrobial activity against vancomycin-resistant Enterococcus faecium CCARM 5029 after 18 hrs by broth microdilution assay in presence of 150 mM NaCl | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Antimicrobial effect of halocidin-derived peptide in a mouse model of Listeria infection. |
AID425042 | Antimicrobial activity against methicillin-resistant Staphylococcus aureus CCARM 3695 after 18 hrs by broth microdilution assay | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Antimicrobial effect of halocidin-derived peptide in a mouse model of Listeria infection. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Research
Studies (14)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 8 (57.14) | 29.6817 |
2010's | 6 (42.86) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 11.68
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.68) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 14 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |